Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders

Pharmacopsychiatry

Volumn 40, Issue 2, 2007, Pages 72-76

  Gerlach, M ^a   Hunnerkopf R ^a   Rothenhofer S ^b   Libal, G ^c   Burger, R ^a   Clement, H W ^d   Fegert, J M ^c   Wewetzer, Ch ^b   Mehler Wex, C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; CHLORPROTHIXENE; CITALOPRAM; DIAZEPAM; FLUOXETINE; LITHIUM ACETATE; LORAZEPAM; MELPERONE; METOPROLOL; PERAZINE; PIPAMPERONE; PREDNISONE; QUETIAPINE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOSIS; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 34247895481     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-972573     Document Type: Article

References (28)

1. Arvanitis LA, Miller BG: Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia. A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233-246
2. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M et al: The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265
3. Bergemann N, Abu-Tair F, Kress KR, Aderjan R, Kopitz J: Therapeutic drug monitoring of quetiapine. The World Journal of Biological Psychiatry 6: 177 FC-004.01
4. DeVane LC, Nemeroff CB: Clinical pharmacokinetics of quetiapine. Clin Pharmacol 2001; 40: 509-522
5. Dragicevic A, Sachse J, Härtter S, Hiemke C, Müller MJ: Serum concentrations of quetiapine and clinical effects. Pharmacopsychiatry 2005; 38: 47-48
6. Gerlach M, Warnke A: Allgemeine Aspekte und Besonderheiten der Neuro-Psychopharmakologie im Kindes- und Jugendalter. In: Gerlach M, Warnke A, Wewetzer Ch, editors. Neuro-Psychopharmaka im Kindes- und Jugendalter. Grundlagen und Therapie. Wien New York: Springer, 2004; 51-60
7. Gerlach M, Rothenhöfer S, Mehler-Wex C, Fegert JM, Schulz E, Wewetzer Ch et al: Therapeutisches Drug-Monitoring in der Kinder- und Jugend-psychiatrie - Grundagen und praktische Empfehlungen. Z Kinder-Jugendpsychiatr 2006; 34: 5-13
8. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A et al: Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 1999; 2: 861-863
9. Giles M, Deuschle M, Kellner S, Shams M, Krumm B, Härtter S et al: Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 2005; 38: 118-121
10. Goldstein J, Arvanitis LA: ICI 204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and high-lights of Phase II clinical trials. CNS Drug Rev 1995; 1: 50-73
11. Guy W: ECDEU assessment manual. Rockville, National Institute of Mental Health, 1976
12. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J et al: National kidney foundation's kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111: 1416-1421
13. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Delopmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167
14. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO et al: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumerate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000; 61: 252-260
15. Mehler-Wex C, Martin M, Wewetzer Ch: Schizophrenie, schizotype und wahnhafte Störungen. In: Gerlach M, Warnke A, Wewetzer Ch, editors. Neuro-Psychopharmaka im Kindes- und Jugendalter. Grundlagen und Therapie. Wien New York: Springer, 2004; 283-290
16. Morselli PL, Cuche H, Zarifian E: Pharmacokinetics of psychotropic drugs in the pediatric patient. In: Mendlewicz J, van Praag HM, editors. Childhood Psychopharmacology: Current concepts. Advances in Biological Psychiatry. Basel: Karger, 1978; 70-86
17. Morselli PL, Bianchetti G, Durand G, Le-Heuzey MF, Zarifian E, Dugas M: Haloperidol plasma level monitoring in pediatric patients. Ther Drug Monit 1979; 1: 35-46
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: 1-266
19. Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812
20. Remschmidt HE, Schulz E, Martin M, Warnke A, Trott GE: Childhood-onset schizophrenia: A history of the concept and recent studies. Schizophrenia Bull 1994; 20: 727-745
21. Remschmidt H, Theisen FM: Schizophrenia and related disorders in children and adolescents. J Neural Transm 2005; Suppl 69: 121-141
22. Retz W, Kornhuber J, Riederer P: Neurotransmission and the ontogeny of human brain. J Neural Transm 1996; 103: 403-419
23. Rothenhöfer S, Mehler-Wex C, Schupp U, Wewetzer Ch, Gerlach M: Therapeutic drug monitoring of quetiapine in child and adolescents. Pharmacopsychiatry 2005; 38: 61-62
24. Sachse J, Köller J, Hartter S, Hiemke C: Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography (HPLC) with column switching and spectrophotometric detection. J Chromatogr B 2006; 830: 342-348
25. Schimmelmann B, Schulze-zur-Wiesch C, Mehler-Wex C, Koch E, Flechtner HH, Gierow B et al: A prospective, open-label study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adol Psychopharmacol , submitted
26. Seeman P, Bzowej NH, Guan H-C, Bergeron C, Becker LE, Reynolds GP et al: Human brain dopamine receptors in children and aging adults. Synapse 1987; 1: 399-404
27. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549-557
28. Wittmann M, Haen E: TDM von Quetiapin. Abstrac Book of Therapeutisches Drug Monitoring von Psychopharmaka. Sölden, Austria, 2006